2010 Cannabis Clinical Trials DEA 
Cannabis Law Report
MARCH 18, 2022
Similar to the early days of the medical cannabis movement, psychedelic drugs such as MDMA, psilocybin, LSD, ketamine and DMT are being developed for therapeutic use in a complex and difficult legal and regulatory environment. The firm’s multidisciplinary team covers commercial, regulatory and legal requirements spanning U.S. Steve Levine.
SpeedWeed
MARCH 18, 2021
Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. One group self-administered cannabis with 12% THC over three weeks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
AUGUST 8, 2020
– because today’s post is a deep dive into everything you need to know about the most popular cannabis compound around. Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol. Researchers believe cannabis contains over 100 unique chemical compounds!
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.
Expert insights. Personalized for you.
52 
Let's personalize your content